panbronchiolitis%20-%20diffuse
PANBRONCHIOLITIS - DIFFUSE
Diffuse panbronchiolitis is an inflammatory disease affecting the respiratory bronchioles.
It causes progressive suppurative and obstructive respiratory disease.
This is an idiopathic disease which is primarily found in Japan, Korea and China.
Predisposition to the disease may be genetically-related but environmental factors should also be considered.
Failure to treat diffuse panbronchiolitis can lead to development of bronchiectasis, progressive failure and death.

Follow Up

  • Follow up & assess patient’s overall clinical response after 6 months of macrolide treatment
  • If patient shows good response w/ macrolide, eg pulmonary function, clinical, radiological findings have improved, complete the treatment for 2 years
  • If symptoms recur after stopping the treatment, resume medication
  • In patients w/ respiratory failure & extensive bronchiectasis, continue treatment for >2 years
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 02 Mar 2017
The placement of personalized inhaler technique reminder labels on dry-powder asthma inhalers may improve the retention of inhaler technique skills after training and potentially extend the benefit of the training onto asthma outcomes, according to a study.
Audrey Abella, 08 Feb 2018
Better clinical efficacy was observed among cancer patients with postoperative hospital-acquired pneumonia (HAP) who received prolonged infusion of the mixed preparation of the broad-spectrum β-lactamase inhibitor tazobactam and β-lactam antibiotic piperacillin (TZP) compared with those who received the traditional regimen, according to a study.

Stephen Padilla, 02 Mar 2017
Use of vitamin D supplementation prevents acute respiratory tract infection, with individuals who are very deficient in vitamin D and those not receiving additional bolus doses benefitting the most, a recent study has found.
01 Jun 2016
Fluticasone furoate is superior to mometasone nasal spray in improving several perceived sensory attributes of allergic rhinitis patients, based on a multicentre, randomised, crossover, prospective study.